Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 6 | 2020 | 670 | 1.000 |
Why?
|
Obesity | 10 | 2021 | 1184 | 0.940 |
Why?
|
Leptin | 4 | 2024 | 78 | 0.870 |
Why?
|
Hyperglycemia | 1 | 2020 | 103 | 0.650 |
Why?
|
Glucocorticoids | 2 | 2020 | 172 | 0.650 |
Why?
|
Bone and Bones | 2 | 2024 | 155 | 0.650 |
Why?
|
Primary Prevention | 1 | 2017 | 137 | 0.530 |
Why?
|
Juglans | 3 | 2021 | 11 | 0.490 |
Why?
|
Follistatin | 3 | 2021 | 44 | 0.480 |
Why?
|
Health Status | 1 | 2017 | 449 | 0.470 |
Why?
|
Anti-Obesity Agents | 3 | 2019 | 12 | 0.460 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 566 | 0.450 |
Why?
|
Nephrosis | 1 | 2013 | 3 | 0.450 |
Why?
|
Hypoparathyroidism | 1 | 2013 | 7 | 0.450 |
Why?
|
Diabetes Complications | 1 | 2014 | 102 | 0.440 |
Why?
|
Risk Assessment | 1 | 2020 | 1912 | 0.430 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 47 | 0.420 |
Why?
|
Hospitalization | 1 | 2020 | 1283 | 0.410 |
Why?
|
Energy Metabolism | 4 | 2024 | 349 | 0.370 |
Why?
|
Neurosecretory Systems | 2 | 2024 | 24 | 0.350 |
Why?
|
Weight Loss | 3 | 2019 | 260 | 0.310 |
Why?
|
Insulin-Like Growth Factor Binding Protein 4 | 2 | 2018 | 5 | 0.300 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 2 | 2018 | 6 | 0.300 |
Why?
|
Blood Glucose | 3 | 2020 | 471 | 0.300 |
Why?
|
Benzazepines | 2 | 2019 | 21 | 0.290 |
Why?
|
Activins | 2 | 2018 | 54 | 0.290 |
Why?
|
Fibronectins | 2 | 2017 | 41 | 0.290 |
Why?
|
Insulin Resistance | 3 | 2021 | 404 | 0.280 |
Why?
|
Metabolic Diseases | 2 | 2017 | 50 | 0.270 |
Why?
|
Double-Blind Method | 7 | 2021 | 669 | 0.240 |
Why?
|
Coronary Artery Disease | 2 | 2018 | 269 | 0.240 |
Why?
|
Humans | 24 | 2024 | 59419 | 0.230 |
Why?
|
Autoantibodies | 2 | 2016 | 175 | 0.220 |
Why?
|
Food Preferences | 2 | 2021 | 55 | 0.210 |
Why?
|
Homeostasis | 1 | 2024 | 342 | 0.200 |
Why?
|
Middle Aged | 13 | 2021 | 16248 | 0.200 |
Why?
|
Fasting | 2 | 2019 | 51 | 0.190 |
Why?
|
Female | 17 | 2021 | 30883 | 0.190 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2021 | 7 | 0.190 |
Why?
|
Myocardial Infarction | 2 | 2018 | 860 | 0.190 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2021 | 13 | 0.180 |
Why?
|
Risk Factors | 3 | 2020 | 5011 | 0.180 |
Why?
|
Thyroid Neoplasms | 1 | 2021 | 77 | 0.180 |
Why?
|
Body Weight | 2 | 2019 | 380 | 0.170 |
Why?
|
Gastrointestinal Hormones | 1 | 2019 | 10 | 0.170 |
Why?
|
Male | 15 | 2021 | 27545 | 0.170 |
Why?
|
Liraglutide | 1 | 2019 | 4 | 0.170 |
Why?
|
Bariatric Surgery | 1 | 2019 | 45 | 0.160 |
Why?
|
Metabolic Syndrome | 2 | 2017 | 148 | 0.160 |
Why?
|
Prefrontal Cortex | 1 | 2019 | 113 | 0.160 |
Why?
|
Eating | 1 | 2019 | 139 | 0.150 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 83 | 0.150 |
Why?
|
Follistatin-Related Proteins | 1 | 2018 | 22 | 0.150 |
Why?
|
Follow-Up Studies | 2 | 2021 | 2327 | 0.150 |
Why?
|
Reproduction | 1 | 2018 | 88 | 0.150 |
Why?
|
Biomarkers, Tumor | 1 | 2021 | 453 | 0.150 |
Why?
|
Prognosis | 3 | 2021 | 1572 | 0.150 |
Why?
|
Appetite Regulation | 1 | 2017 | 8 | 0.150 |
Why?
|
Nuts | 1 | 2017 | 7 | 0.140 |
Why?
|
Creatine Kinase, MB Form | 1 | 2017 | 10 | 0.140 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 2016 | 158 | 0.140 |
Why?
|
Functional Food | 1 | 2017 | 32 | 0.140 |
Why?
|
Diabetic Ketoacidosis | 1 | 2016 | 12 | 0.140 |
Why?
|
Incidence | 1 | 2020 | 1238 | 0.130 |
Why?
|
Cost of Illness | 1 | 2017 | 155 | 0.130 |
Why?
|
Receptor, Insulin | 1 | 2016 | 47 | 0.130 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2017 | 155 | 0.130 |
Why?
|
White Matter | 1 | 2017 | 111 | 0.130 |
Why?
|
Glycoproteins | 1 | 2017 | 194 | 0.130 |
Why?
|
Cerebral Cortex | 1 | 2017 | 253 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2021 | 1053 | 0.130 |
Why?
|
Hypoglycemic Agents | 1 | 2017 | 211 | 0.120 |
Why?
|
Cross-Over Studies | 3 | 2021 | 143 | 0.120 |
Why?
|
Bone Diseases, Metabolic | 1 | 2014 | 21 | 0.120 |
Why?
|
Diet | 1 | 2019 | 634 | 0.120 |
Why?
|
Comorbidity | 1 | 2017 | 1089 | 0.110 |
Why?
|
WT1 Proteins | 1 | 2013 | 6 | 0.110 |
Why?
|
GATA3 Transcription Factor | 1 | 2013 | 15 | 0.110 |
Why?
|
Biomedical Research | 1 | 2016 | 250 | 0.110 |
Why?
|
Cognitive Dysfunction | 1 | 2017 | 262 | 0.110 |
Why?
|
Parathyroid Hormone | 1 | 2013 | 43 | 0.110 |
Why?
|
Prevalence | 1 | 2017 | 1284 | 0.110 |
Why?
|
Cues | 3 | 2019 | 75 | 0.100 |
Why?
|
Aged | 5 | 2020 | 13334 | 0.100 |
Why?
|
Animals | 4 | 2024 | 19639 | 0.100 |
Why?
|
Felty Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
|
Retrospective Studies | 2 | 2021 | 6000 | 0.100 |
Why?
|
Neurons | 1 | 2017 | 859 | 0.100 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 820 | 0.100 |
Why?
|
Brain | 2 | 2017 | 1487 | 0.090 |
Why?
|
Young Adult | 3 | 2018 | 4314 | 0.090 |
Why?
|
Postprandial Period | 2 | 2019 | 19 | 0.080 |
Why?
|
Histones | 1 | 2011 | 463 | 0.080 |
Why?
|
United States | 1 | 2020 | 7515 | 0.070 |
Why?
|
Energy Intake | 2 | 2019 | 213 | 0.070 |
Why?
|
Percutaneous Coronary Intervention | 2 | 2018 | 167 | 0.060 |
Why?
|
Cognition | 2 | 2019 | 459 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 903 | 0.060 |
Why?
|
Body Mass Index | 2 | 2017 | 885 | 0.050 |
Why?
|
Adult | 5 | 2019 | 15762 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2017 | 2473 | 0.040 |
Why?
|
Glicentin | 1 | 2019 | 1 | 0.040 |
Why?
|
Oxyntomodulin | 1 | 2019 | 1 | 0.040 |
Why?
|
Peptide YY | 1 | 2019 | 3 | 0.040 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 20 | 0.040 |
Why?
|
Protective Factors | 1 | 2019 | 34 | 0.040 |
Why?
|
Reward | 1 | 2019 | 84 | 0.040 |
Why?
|
Lipoproteins | 1 | 2019 | 84 | 0.040 |
Why?
|
Breakfast | 1 | 2017 | 2 | 0.040 |
Why?
|
Satiety Response | 1 | 2017 | 5 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 2037 | 0.040 |
Why?
|
Creatine | 1 | 2017 | 26 | 0.040 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 98 | 0.040 |
Why?
|
Diffusion Tensor Imaging | 1 | 2017 | 66 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2017 | 102 | 0.030 |
Why?
|
Lipids | 1 | 2019 | 306 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2016 | 12 | 0.030 |
Why?
|
Azathioprine | 1 | 2016 | 23 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 1027 | 0.030 |
Why?
|
Immunomodulation | 1 | 2016 | 27 | 0.030 |
Why?
|
Risk | 1 | 2017 | 373 | 0.030 |
Why?
|
Coronary Angiography | 1 | 2017 | 171 | 0.030 |
Why?
|
Inpatients | 1 | 2019 | 295 | 0.030 |
Why?
|
Remission Induction | 1 | 2016 | 137 | 0.030 |
Why?
|
Boston | 1 | 2017 | 331 | 0.030 |
Why?
|
Rituximab | 1 | 2016 | 82 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2016 | 99 | 0.030 |
Why?
|
Dexamethasone | 1 | 2016 | 194 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 432 | 0.030 |
Why?
|
Antigens, CD | 1 | 2016 | 343 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 303 | 0.030 |
Why?
|
Sex Factors | 1 | 2017 | 961 | 0.030 |
Why?
|
Emotions | 1 | 2016 | 217 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2017 | 369 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2017 | 1225 | 0.030 |
Why?
|
Biomarkers | 1 | 2018 | 1199 | 0.030 |
Why?
|
Aging | 1 | 2017 | 723 | 0.020 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 24 | 0.020 |
Why?
|
Cohort Studies | 1 | 2017 | 2443 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2016 | 1449 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 537 | 0.020 |
Why?
|
Autoantigens | 1 | 2011 | 125 | 0.020 |
Why?
|
Prospective Studies | 1 | 2017 | 3095 | 0.020 |
Why?
|
Exercise | 1 | 2017 | 917 | 0.020 |
Why?
|
Neutrophils | 1 | 2011 | 352 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 325 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2011 | 5095 | 0.010 |
Why?
|
Adolescent | 1 | 2011 | 5918 | 0.010 |
Why?
|